ELVN-001 is made to look more like Terns’ TERN-701.

A pivotal trial will test the KRAS G12D degrader setidegrasib plus chemo in first-line PDAC.

Data from the Ilustro trial support the initiation of the phase 3 Lucerna study.

The group’s on/off KRAS G12C inhibitor looks good, though patient numbers are small.

Four months after yielding first-in-human data INCA33890 enters phase 3.

But Tevimbra’s role looks shaky as adverse events loom.